These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 20811695

  • 1. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M, Kloboves Prevodnik V, Lavrencak J, Jezersek Novakovic B.
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [Abstract] [Full Text] [Related]

  • 2. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 3. The predictive significance of CD20 expression in B-cell lymphomas.
    Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ.
    Diagn Pathol; 2011 Apr 12; 6():33. PubMed ID: 21486448
    [Abstract] [Full Text] [Related]

  • 4. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
    Kusenda J, Babusíková O.
    Neoplasma; 2004 Apr 12; 51(2):97-102. PubMed ID: 15190418
    [Abstract] [Full Text] [Related]

  • 5. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 12; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 6. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K, Terui Y.
    Gan To Kagaku Ryoho; 2009 Apr 12; 36(4):548-51. PubMed ID: 19381025
    [Abstract] [Full Text] [Related]

  • 7. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
    Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S, Gillor D, Müller M, Van Lunzen J, Wolf T, Bogner JR, Wasmuth JC, Christ H, Fätkenheuer G, Hoffmann C.
    AIDS; 2012 Feb 20; 26(4):457-64. PubMed ID: 22112600
    [Abstract] [Full Text] [Related]

  • 8. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep 20; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

  • 9. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA, Czerwinski DK, Levy R.
    Clin Cancer Res; 1999 Mar 20; 5(3):611-5. PubMed ID: 10100713
    [Abstract] [Full Text] [Related]

  • 10. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
    Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K.
    Clin Cancer Res; 2009 Apr 01; 15(7):2523-30. PubMed ID: 19276251
    [Abstract] [Full Text] [Related]

  • 11. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.
    Clin Cancer Res; 2008 Mar 01; 14(5):1561-70. PubMed ID: 18316581
    [Abstract] [Full Text] [Related]

  • 12. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY, Lin TY, Jiang WQ, Zhang L, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ.
    Ai Zheng; 2004 Dec 01; 23(12):1681-6. PubMed ID: 15601560
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
    van Dalen A, Favier J, Baumgartner L, Hasholzner U, de Bruijn H, Dobbler D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Einarsson R.
    Anticancer Res; 1999 Dec 01; 19(4A):2523-6. PubMed ID: 10470187
    [Abstract] [Full Text] [Related]

  • 14. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H.
    Am J Surg Pathol; 2013 Apr 01; 37(4):563-70. PubMed ID: 23426122
    [Abstract] [Full Text] [Related]

  • 15. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM.
    J Cutan Pathol; 2005 Oct 01; 32(9):616-21. PubMed ID: 16176299
    [Abstract] [Full Text] [Related]

  • 16. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.
    Exp Hematol; 2010 Mar 01; 38(3):213-21. PubMed ID: 20056126
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
    Saito B, Shiozawa E, Yamochi-Onizuka T, Adachi D, Nakamaki T, Tomoyasu S, Omine M, Mitsuya T, Takimoto M, Ota H.
    Pathol Int; 2004 Sep 01; 54(9):667-74. PubMed ID: 15363034
    [Abstract] [Full Text] [Related]

  • 18. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
    Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ.
    Br J Haematol; 2008 Apr 01; 141(1):36-40. PubMed ID: 18324964
    [Abstract] [Full Text] [Related]

  • 19. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.
    Leuk Res; 2006 May 01; 30(5):625-31. PubMed ID: 16289746
    [Abstract] [Full Text] [Related]

  • 20. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.
    Ai Zheng; 2007 Aug 01; 26(8):837-42. PubMed ID: 17697543
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.